Advancements in Prognostic and Predictive Biomarkers for Advanced Prostate Cancer
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 28 February 2026 | Viewed by 9
Special Issue Editor
Interests: prostate cancer; biomarkers; androgen pathway inhibitors; circulating cell-free DNA; treatment toxicity; patient reported outcomes; clinical trials; early phase clinical trials
Special Issue Information
Dear Colleagues,
The treatment landscape for advanced prostate cancer is quickly evolving. A variety of systemic agents have recently been approved across multiple drug classes, including radio-pharmaceuticals, poly (ADP-ribose) polymerase (parp) inhibitors, and novel T-cell-engaging antibodies, rapidly transforming the treatment landscape. The multiple disease states in which systemic therapies are indicated, ranging from high-risk localized disease to metastatic castration-resistant disease, further compounds the complexity of management. Important questions and dilemmas faced by investigators and clinicians include the optimization of treatment selection, treatment sequencing, and combination strategies. The heterogeneity in disease phenotype and treatment response requires a biomarker-directed strategy to enhance patient outcomes.
Accordingly, we recently witnessed long-awaited and encouraging developments in biomarker discovery and validation. Notable successes in the past decade have included the approval of parp inhibitors for homologous-recombination-altered tumours, circulating cell-free tumour DNA quantification and sequencing, and cell surface expression of Prostate-Specific Membrane Antigen (PSMA) as an imaging and therapeutic target. We should expect a new wave of clinically actionable biomarkers as many have shown promise in recent validation studies.
This Special Issue will highlight original research advancing the field of predictive and prognostic biomarkers in advanced prostate cancer, as well as review articles detailing recent developments. Please note that because this Special Issue is focused on molecular research, pure clinical research will not be accepted. But clinical submissions involving biomolecular experiments are welcome.
This Special Issue is led by Dr. Daniel Khalaf and assisted by our GE's Assistant Editor, Dr. Simon Fu (Department of Oncology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand).
Dr. Daniel Khalaf
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biomarkers
- predictive biomarkers
- prognostic biomarkers
- genomic biomarkers
- biomarker directed therapy
- advanced prostate cancer
- metastatic prostate cancer
- circulating tumour DNA
- precision oncology
- systemic therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
